Sonntag, 7. März 2021
Navigation öffnen
Anzeige:
Imfinzi NSCLC
Imfinzi NSCLC
JOURNAL ONKOLOGIE – STUDIE

NivoMela Adjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk Melanoma

Rekrutierend

NCT-Nummer:
NCT04309409

Studienbeginn:
Juli 2020

Letztes Update:
16.02.2021

Wirkstoff:
Nivolumab

Indikation (Clinical Trials):
Melanoma

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
Phase 3

Sponsor:
University Hospital, Essen

Collaborator:
-

Studienleiter

Dirk Schadendorf, Prof. Dr.
Principal Investigator
University Hospital, Essen

Kontakt

Dirk Schadendorf, Prof. Dr.
Kontakt:
Phone: +49 (0) 201 / 723-2431
E-Mail: dirk.schadendorf@uk-essen.de
» Kontaktdaten anzeigen

Studienlocations (3 von 20)

Universitätsklinikum Würzburg - Klinik für Dermatologie, Venerologie und Allergologie
97080 Würzburg
(Bayern)
GermanyNoch nicht rekrutierend» Google-Maps
Ansprechpartner:
Bastian Schilling, Prof. Dr.
E-Mail: Schilling_B@ukw.de
» Ansprechpartner anzeigen
Universitätsmedizin Rostock -Klinik und Poliklinik für Dermatologie und Venerologie
18057 Rostock
(Mecklenburg-Vorpommern)
GermanyNoch nicht rekrutierend» Google-Maps
Ansprechpartner:
Julia Katharina Tietze, Dr. med.
E-Mail: julia.tietze@med.uni-rostock.de
» Ansprechpartner anzeigen
St. Josef-Hospital - Dermatologische Studienambulanz
44791 Bochum
(Nordrhein-Westfalen)
GermanyRekrutierend» Google-Maps
Ansprechpartner:
Thilo Gambichler, Prof. Dr.
E-Mail: t.gambichler@klinikum-bochum.de
» Ansprechpartner anzeigen
Universitätsklinik Carl Gustav Carus der Technischen Universität Dresden - Klinik und Poliklinik für Dermatologie
01307 Dresden
(Sachsen)
GermanyRekrutierend» Google-Maps
Ansprechpartner:
Friedegund Meier, Prof. Dr.
E-Mail: friedegund.meier@uniklinikum-dresden.de
» Ansprechpartner anzeigen
University Hospital Essen, Department of Dermatology, Skin Cancer Center
45122 Essen
(Nordrhein-Westfalen)
GermanyRekrutierend» Google-Maps
Ansprechpartner:
Dirk Schadendorf, Prof. Dr.
E-Mail: dirk.schadendorf@uk-essen.de
» Ansprechpartner anzeigen
Universitätsklinikum Freiburg - Klinik für Dermatologie und Venerologie
79106 Freiburg
(Baden-Württemberg)
GermanyRekrutierend» Google-Maps
Ansprechpartner:
Frank Meiß, Dr. med.
E-Mail: frank.meiss@uniklinik-freiburg.de
» Ansprechpartner anzeigen
Universitätsklinikum Gießen und Marburg GmbH - Klinik für Dermatologie und Allergologie
35392 Gießen
(Hessen)
GermanyRekrutierend» Google-Maps
Ansprechpartner:
Daniela Göppner, PD Dr. med.
E-Mail: daniela.goeppner@derma.med.uni-giessen.de
» Ansprechpartner anzeigen
Universitätsklinikum Hamburg-Eppendorf - Hauttumorzentrum
20246 Hamburg
(Hamburg)
GermanyRekrutierend» Google-Maps
Ansprechpartner:
Christoffer Gebhardt, Prof. Dr.
E-Mail: ch.gebhardt@uke.de
» Ansprechpartner anzeigen
Universitätsklinikum Schleswig-Holstein, Campus Kiel - Dermatologie
24105 Kiel
(Schleswig-Holstein)
GermanyRekrutierend» Google-Maps
Ansprechpartner:
Axel Hauschild, Prof. Dr.
E-Mail: ahauschild@dermatology.uni-kiel.de
» Ansprechpartner anzeigen
Universitätsklinikum Leipzig - Klinik u. Poliklinik f. Dermatologie, Venerologie u. Allergologie
04103 Leipzig
(Sachsen)
GermanyRekrutierend» Google-Maps
Ansprechpartner:
Jan C. Simon, Prof. Dr.
E-Mail: jan.simon@medizin.uni-leipzig.de
» Ansprechpartner anzeigen
Universitätsklinikum Mannheim - Klinik f. Dermatologie, Venerologie u. Allergologie
68167 Mannheim
(Baden-Württemberg)
GermanyRekrutierend» Google-Maps
Ansprechpartner:
Jochen S. Utikal, Prof. Dr.
E-Mail: jochen.utikal@umm.de
» Ansprechpartner anzeigen
Klinikum der Universität München - Klinik und Poliklinik für Dermatologie und Allergologie
80337 München
(Bayern)
GermanyRekrutierend» Google-Maps
Ansprechpartner:
Max Schlaak, PD Dr.
E-Mail: Max.Schlaak@med.uni-muenchen.de
» Ansprechpartner anzeigen
Universitätsklinikum Münster - Zentrale Studienkoordination für innovative Dermatologie (ZID)
48149 Münster
(Nordrhein-Westfalen)
GermanyRekrutierend» Google-Maps
Ansprechpartner:
Carsten Weishaupt, Dr. med.
E-Mail: carsten.weishaupt@ukmuenster.de
» Ansprechpartner anzeigen
Fachklinik Hornheide - Internistische Onkologie
48157 Münster
(Nordrhein-Westfalen)
GermanyRekrutierend» Google-Maps
Ansprechpartner:
Michael Fluck, Dr. med.
E-Mail: michael.fluck@fachklinik-hornheide.de
» Ansprechpartner anzeigen
Harzklinikum Dorothea Christiane Erxleben - Klinik für Dermatologie & Allergologie
06484 Quedlinburg
(Sachsen-Anhalt)
GermanyRekrutierend» Google-Maps
Ansprechpartner:
Jens Ulrich, Prof. Dr.
E-Mail: jens.ulrich@harzklinikum.com
» Ansprechpartner anzeigen
Universitätsklinikum Tübingen - Dermatoonkologie
72076 Tübingen
(Baden-Württemberg)
GermanyRekrutierend» Google-Maps
Ansprechpartner:
Thomas K Eigentler, Prof. Dr.
E-Mail: thomas.eigentler@med.uni-tuebingen.de
» Ansprechpartner anzeigen
Alle anzeigen

Studien-Informationen

Detailed Description:

The NivoMela trial is a randomized, controlled, prospective, multi-center national phase III

trial with biomarker-based risk stratification.

Stage II melanoma patients having undergone surgery of the malignant melanoma will be

screened using the MelaGenix GEP score to identify patients at high risk for relapse. It is

expected, that 61% of screened patients will belong to this group.

Patients with a risk score of > 0.0 (HR 1.48, 1.11-1.98) corresponding to high risk of

relapse will be randomized at a ratio of 2:1 to receive either nivolumab as adjuvant

treatment (arm A) or observation only (arm B).

Stratification factors for randomization are:

1. Tumor stage: IIA versus IIB versus IIC

2. Gender: Female versus Male

3. Site of primary tumor: extremities versus trunk versus head &neck

All screened patients with a risk score of ≤ 0.0 who are not eligible for randomization will

be followed for RFS, DMFS and OS for at least 5 years according to German Follow-up

guidelines (Arm C).

Various factors that could potentially predict clinical response and incidence of AEs to

treatment with nivolumab will be investigated in peripheral blood and tumor specimen taken at

baseline. Data from these investigations will be evaluated for associations with clinical

efficacy (eg, ORR, PFS, OS) and safety/toxicity (AE). The samples may also be used for

exploratory analyses to assess biomarkers associated with melanoma and/or with immunotherapy

treatment.

Ein-/Ausschlusskriterien

Inclusion Criteria:

1. Histologically confirmed diagnosis of stage II (AJCCv8) melanoma arising from a

primary cutaneous site after surgery therapy

2. Sentinel node biopsy (SNB) without detection of melanoma deposits

3. Randomization not later than 12 weeks after SNB procedure

4. Tumor tissue from primary tumor must be provided for biomarker analyses. In order to

be randomized, a subject must be classified by MelaGenix risk analysis.

5. Men and women at the age of 18 to 80 years

6. Signed written, informed consent

7. Patients must be willing and able to comply with scheduled visits, treatment schedule,

laboratory testing, and other requirements of the study

8. Minimum life expectancy of five years excluding their melanoma diagnosis

9. ECOG performance status of 0-1

10. Screening laboratory values must meet the following criteria and should be obtained

within 14 days prior to randomization:

- White blood cells (WBC) ≥ 2000/μL

- Neutrophils ≥ 1500/μL

- Platelets ≥ 100 x103/μL

- Hemoglobin ≥ 9.0 g/dL

- Serum creatinine ≤ 1.5xUL

- Creatinine clearance (CrCl) ≥ 40mL/min (using the Cockcroft-Gault formula)

- AST / ALT ≤ 3 x ULN

- Total Bilirubin ≤ 1.5 x ULN (except subjects with Gilbert Syndrome, who may have

total bilirubin < 3.0 mg/dL)

11. Negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent

units of HCG) for women of childbearing potential (WOCBP) within 72 hours prior to

registration.

Women will be considered to be of childbearing potential unless surgically sterilized

(hysterectomy, bilateral tubal ligation, or bilateral oophorectomy), or being

post-menopausal for at least 24 months or being amenorrheic for > 12 months and

follicle-stimulating hormone (FSH) levels ≥ 40 IU/L.

12. WOCBP and male patients with partners of childbearing potential must agree to always

use a highly effective form of contraception according to CTFG during the course of

this study and for at least 5 months after last dose of study medication (in Arm A

only).

Exclusion Criteria:

1. History of primary uveal or mucosal melanoma

2. No access to sufficient tumor tissue of primary tumor

3. SNB procedure > 12 weeks before randomization

4. Prior active malignancy within the previous 3 years except for locally curable cancers

that have been apparently cured, such as: basal or squamous cell skin cancer,

superficial bladder cancer or carcinoma in situ of the prostate, cervix, or breast.

Exception: Participants with a history of non-ulcerated cutaneous/acral primary

melanoma <1 mm in depth with no nodal involvement are allowed in this trial.

5. Prior or planned therapy with Interferon alpha, CTLA4 or PD-1 / PD L1 antibodies

6. Use of any investigational or non-registered product (drug or vaccine) other than the

study treatment

7. Administration of live vaccines within 4 weeks before start of study therapy

8. Any immunosuppressive therapy given within the past 30 days

9. Active psychiatric or addictive disorders that may compromise his/her ability to give

informed consent or to comply with the trial procedures

10. Active immune deficiencies or significant autoimmune disease

11. Serious cardiac, gastrointestinal, hepatic or pulmonary disease which would reduce

life expectancy to less than five years

12. Serious intercurrent illness, requiring hospitalization

13. Other serious illnesses, e.g., serious infections requiring antibiotics or bleeding

disorders

14. The patient is known to be positive for Human Immunodeficiency Virus (HIV) or other

active chronic infections (HBV, HCV) or has another confirmed or suspected

immunosuppressive or immunodeficient condition

15. Any serious or uncontrolled medical disorder that, in the opinion of the investigator,

may increase the risk associated with study participation or study drug

administration, impair the ability of the subject to receive protocol therapy, or

interfere with the interpretation of study results.

16. Hypersensitivity to the active substance or to any of the excipients

17. Participation in another clinical study within the 30 days before registration

18. For female patients: Pregnancy or breast-feeding

19. For WOCBP and male patients with partners of childbearing potential: Refusal or

inability to use effective means of contraception

20. Lack of availability for clinical follow-up assessments

21. Legal incapacity or limited legal capacity

Studien-Rationale

Primary outcome:

1. Relapse-Free Survival (RFS) rates (Time Frame - 5 years):
Determination of efficacy of nivolumab in a biomarker-selected high-risk-enriched stage II melanoma patient population in comparison to control receiving observation only in a 2 (Arm A=nivolumab) : 1 (Arm B=observation) randomization, as measured by Relapse-Free Survival (RFS) rates at 36 and 60 months. RFS is defined as the time from date of registration until documented tumor progression date or date of death of any cause, whichever occurs first in all patients tested with the MelaGenix gene expression profiling (GEP).



Secondary outcome:

1. Distant metastasis-free survival (DMFS) rates (Time Frame - 5 years):
DMFS rates at 36 and 60 months

2. Melanoma-specific survival (MSS) rates (Time Frame - 5 years):
MSS rates at 36 and 60 months

3. Overall survival (OS) rates (Time Frame - 5 years):
OS rates at 36 and 60 months

4. Adverse events ≥ Grade 3 according to CTCAE Version 5.0 criteria (Safety / Toxicity) (Time Frame - Arm A: Until 100 days after discontinuation of dosing of the investigational product; Arm B: Until 1 year after patient´s written consent):
All adverse events ≥ Grade 3 according to CTCAE Version 5.0 criteria, that are definitely, probably, or possibly related to the administration of the investigational agent

5. Clinical utility/decision impact of the MelaGenix Gene Expression Profiling (GEP) Score in stratifying patients for adjuvant therapy (Time Frame - 5 years):
Patients with a risk score of > 0.0 (HR 1.48, 1.11-1.98) will be classified as high risk for relapse. It is expected, that 61% of screened patients will belong to this group. Patients with a risk score of score of ≤ 0.0 will be classified as low risk for relapse.

Studien-Arme

  • Experimental: Nivolumab (Arm A)
    Patients with a risk score of > 0.0 corresponding to high risk of relapse (randomized): Nivolumab will be applied at a flat dose of 480 mg given as 60-minute iv infusion every 4 weeks for 12 doses over 1 year. Afterwards these patients will receive intense clinical follow up according German Follow up guidelines.
  • No Intervention: Observation, High Risk (Arm B)
    Patients with a risk score of > 0.0 corresponding to high risk of relapse (randomized): Control group (observation only). These patients will receive intense clinical follow up but no further specific therapy according German Follow up guidelines.
  • No Intervention: Observation, Low Risk (Arm C)
    Patients with a risk score of ≤ 0.0 corresponding to low risk of relapse who are not eligible for randomization: These patients will receive intense clinical follow up but no further specific therapy according German Follow up guidelines. Documentation of clinical outcome of these patients.

Geprüfte Regime

  • Nivolumab (Opdivo):
    480 mg nivolumab fixed dose given as 60-minute iv infusion every 4 weeks for 12 doses over 1 year

Quelle: ClinicalTrials.gov


Das könnte Sie auch interessieren

Frauenärzte warnen vor Folgen von Bewegungsmangel

Frauenärzte warnen vor Folgen von Bewegungsmangel
© Picture-Factory / Fotolia.com

Das Leben des Stubenhockers ist riskant: Wer körperliche Bewegung und sportliche Aktivitäten scheut, verzichtet auf einen Universalschlüssel zur Förderung der Gesundheit und zur Prävention zahlreicher schwerer Erkrankungen - Männer wie Frauen, Jung wie Alt. „Der heutige Mensch ist nicht für körperliche Passivität geschaffen. Die Evolution hat ihn noch nicht an die überwiegend sitzenden Tätigkeiten der Zivilisationsgesellschaft...

Brustkrebs: Wissen schafft Mut

Brustkrebs: Wissen schafft Mut
© drubig-photo / Fotolia.com

Jede zehnte Frau in Deutschland ist im Laufe ihres Lebens von Brustkrebs betroffen. Damit ist das Mammakarzinom mit 65.500 Neuerkrankungen pro Jahr der häufigste Tumor bei Frauen. Die Diagnose wirft Fragen auf: Welche Therapie ist die richtige? Wo bekomme ich Hilfe? Die Deutsche Krebshilfe unterstützt Krebspatienten bei ihrem Kampf gegen die Erkrankung. Sie bietet allen Betroffenen eine kostenfreie telefonische Beratung an und hält allgemeinverständliche...

Als Krebspatient auf Reisen – hilfreiche Tipps

Als Krebspatient auf Reisen – hilfreiche Tipps
© Jenny Sturm / Fotolia.com

Ein Kurzurlaub in der Therapiepause – das hört sich für viele Betroffene verlockend an. Mal abschalten und die physischen und psychischen Belastungen der Erkrankung vorübergehend hinter sich lassen. Aber: Kann ich das als Krebspatient? Und worauf ist zu achten? Diese und weitere Fragen zum Thema „Reisen mit Krebs“ beantwortet der Krebsinformationsdienst des Deutschen Krebsforschungszentrums täglich von 08:00 Uhr bis 20:00 Uhr telefonisch unter 0800-420...